Oragenics to sell 8.1M shares at 55c in public offering

Oragenics has entered into a placement agency agreement for the purchase and sale of 8,106,584 shares of its common stock at an offering price of $0.55 per share. The closing of the public offering is expected to occur on or about September 5, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering are anticipated to be approximately $4.45 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. Dawson James Securities, Inc. is acting as the sole placement agent for the offering.